Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Timothy E Albertson; Willis S. Bowman; Richart W Harper; Regina M. Godbout; Susan Murin

doi:10.2147/COPD.S191845

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Timothy E Albertson, Willis S. Bowman, Richart W Harper, Regina M. Godbout, Susan Murin

Pulmonary, Critical Care, and Sleep Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

Original language	English (US)
Pages (from-to)	1251-1265
Number of pages	15
Journal	International journal of chronic obstructive pulmonary disease
Volume	14
DOIs	https://doi.org/10.2147/COPD.S191845
State	Published - Jan 1 2019

Keywords

COPD
fixed-dose combination inhalers
LABA
LAMA
long-acting beta2-adrenergic agonists
long-acting muscarinic antagonists
umeclidinium bromide
vilanterol trifenatate

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.2147/COPD.S191845

Fingerprint Dive into the research topics of 'Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD'. Together they form a unique fingerprint.

Cite this

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. / Albertson, Timothy E; Bowman, Willis S.; Harper, Richart W; Godbout, Regina M.; Murin, Susan.

In: International journal of chronic obstructive pulmonary disease, Vol. 14, 01.01.2019, p. 1251-1265.

Research output: Contribution to journal › Review article › peer-review

@article{f9e0ffc75880471a888b7907bd50e56e,

title = "Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD",

abstract = "The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.",

keywords = "COPD, fixed-dose combination inhalers, LABA, LAMA, long-acting beta2-adrenergic agonists, long-acting muscarinic antagonists, umeclidinium bromide, vilanterol trifenatate",

author = "Albertson, {Timothy E} and Bowman, {Willis S.} and Harper, {Richart W} and Godbout, {Regina M.} and Susan Murin",

year = "2019",

month = jan,

day = "1",

doi = "10.2147/COPD.S191845",

language = "English (US)",

volume = "14",

pages = "1251--1265",

journal = "International Journal of COPD",

issn = "1176-9106",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

AU - Albertson, Timothy E

AU - Bowman, Willis S.

AU - Harper, Richart W

AU - Godbout, Regina M.

AU - Murin, Susan

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

AB - The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

KW - COPD

KW - fixed-dose combination inhalers

KW - LABA

KW - LAMA

KW - long-acting beta2-adrenergic agonists

KW - long-acting muscarinic antagonists

KW - umeclidinium bromide

KW - vilanterol trifenatate

UR - http://www.scopus.com/inward/record.url?scp=85068874913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068874913&partnerID=8YFLogxK

U2 - 10.2147/COPD.S191845

DO - 10.2147/COPD.S191845

M3 - Review article

C2 - 31239659

AN - SCOPUS:85068874913

VL - 14

SP - 1251

EP - 1265

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this